201 related articles for article (PubMed ID: 37626050)
1. The m6A modification-mediated OGDHL exerts a tumor suppressor role in ccRCC by downregulating FASN to inhibit lipid synthesis and ERK signaling.
Shi J; Miao D; Lv Q; Wang K; Wang Q; Liang H; Yang H; Xiong Z; Zhang X
Cell Death Dis; 2023 Aug; 14(8):560. PubMed ID: 37626050
[TBL] [Abstract][Full Text] [Related]
2. FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability.
Xu Y; Zhou J; Li L; Yang W; Zhang Z; Zhang K; Ma K; Xie H; Zhang Z; Cai L; Gong Y; Gong K
Int J Biol Sci; 2022; 18(15):5943-5962. PubMed ID: 36263177
[TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine-modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axis-regulated Hippo pathway.
Miao D; Wang Q; Shi J; Lv Q; Tan D; Zhao C; Xiong Z; Zhang X
Cancer Commun (Lond); 2023 Apr; 43(4):480-502. PubMed ID: 36860124
[TBL] [Abstract][Full Text] [Related]
4. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis.
Zhuang C; Zhuang C; Luo X; Huang X; Yao L; Li J; Li Y; Xiong T; Ye J; Zhang F; Gui Y
J Cell Mol Med; 2019 Mar; 23(3):2163-2173. PubMed ID: 30648791
[TBL] [Abstract][Full Text] [Related]
5. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
6. METTL14-mediated N
Liu Z; Sun T; Piao C; Zhang Z; Kong C
Cell Commun Signal; 2022 Mar; 20(1):36. PubMed ID: 35305660
[TBL] [Abstract][Full Text] [Related]
7. The m
He Y; Chen Y; Li Z; Wu C
J Cancer Res Clin Oncol; 2024 Jan; 150(2):30. PubMed ID: 38270643
[TBL] [Abstract][Full Text] [Related]
8. Aberrant activation of m6A demethylase FTO renders HIF2α
Zhang C; Chen L; Lou W; Su J; Huang J; Liu A; Xu Y; He H; Gao Y; Xu D; Li Q
Sci Transl Med; 2021 Sep; 13(613):eabf6045. PubMed ID: 34586831
[TBL] [Abstract][Full Text] [Related]
9. Interplay between RNA Methylation Eraser FTO and Writer METTL3 in Renal Clear Cell Carcinoma Patient Survival.
Zhao J; Lu L
Recent Pat Anticancer Drug Discov; 2021; 16(3):363-376. PubMed ID: 33563180
[TBL] [Abstract][Full Text] [Related]
10. A Novel Oxoglutarate Dehydrogenase-Like Mediated miR-214/TWIST1 Negative Feedback Loop Inhibits Pancreatic Cancer Growth and Metastasis.
Liu Y; Meng F; Wang J; Liu M; Yang G; Song R; Zheng T; Liang Y; Zhang S; Yin D; Wang J; Yang H; Pan S; Sun B; Han J; Sun J; Lan Y; Wang Y; Liu X; Zhu M; Cui Y; Zhang B; Wu D; Liang S; Liu Y; Song X; Lu Z; Yang J; Li M; Liu L
Clin Cancer Res; 2019 Sep; 25(17):5407-5421. PubMed ID: 31175094
[TBL] [Abstract][Full Text] [Related]
11. MiR-155 regulates m
Yang W; Xie L; Wang P; Zhuang C
Cell Signal; 2022 Mar; 91():110217. PubMed ID: 34921979
[TBL] [Abstract][Full Text] [Related]
12. E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis.
Shen D; Gao Y; Huang Q; Xuan Y; Yao Y; Gu L; Huang Y; Zhang Y; Li P; Fan Y; Tang L; Du S; Wu S; Wang H; Wang C; Gong H; Pang Y; Ma X; Wang B; Zhang X
Cancer Lett; 2021 Aug; 514():48-62. PubMed ID: 34019961
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
14. MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2.
Xiao W; Wang C; Chen K; Wang T; Xing J; Zhang X; Wang X
EBioMedicine; 2020 Jan; 51():102622. PubMed ID: 31901870
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma.
Wang Y; Feng YC; Gan Y; Teng L; Wang L; La T; Wang P; Gu Y; Yan L; Li N; Zhang L; Wang L; Thorne RF; Zhang XD; Cao H; Shao FM
J Exp Clin Cancer Res; 2022 Aug; 41(1):260. PubMed ID: 36028903
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1.
Yang W; Zhang K; Li L; Xu Y; Ma K; Xie H; Zhou J; Cai L; Gong Y; Gong K
J Exp Clin Cancer Res; 2021 Mar; 40(1):92. PubMed ID: 33691743
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling.
Li JK; Chen C; Liu JY; Shi JZ; Liu SP; Liu B; Wu DS; Fang ZY; Bao Y; Jiang MM; Yuan JH; Qu L; Wang LH
Mol Cancer; 2017 Jun; 16(1):111. PubMed ID: 28659173
[TBL] [Abstract][Full Text] [Related]
18. MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria-dependent dephosphorylation of EGFR.
Luo L; Wei D; Pan Y; Wang QX; Feng JX; Yu B; Kang T; Luo J; Yang J; Gao S
Cancer Commun (Lond); 2023 Jul; 43(7):808-833. PubMed ID: 37378422
[TBL] [Abstract][Full Text] [Related]
19. ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway.
Xu J; Wang Y; Jiang J; Yin C; Shi B
J Transl Med; 2023 Jan; 21(1):56. PubMed ID: 36717944
[TBL] [Abstract][Full Text] [Related]
20. N6‑methyladenosine RNA methylation regulators participate in malignant progression and have prognostic value in clear cell renal cell carcinoma.
Zheng Z; Mao S; Guo Y; Zhang W; Liu J; Li C; Yao X
Oncol Rep; 2020 May; 43(5):1591-1605. PubMed ID: 32323803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
